You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫療集團(08225.HK)一季度收入2622.6萬元 同比上升21.58%
格隆匯 05-13 20:51

格隆匯5月13日丨中國醫療集團(08225.HK)公吿,截至2021年3月31日止三個月,集團錄得營業收入人民幣2622.6萬元,較2020年同期營業收入上升21.58%。集團錄得期除税前利潤人民幣1530.4萬元,較2020年同期除税前利潤上升27.25%。截至2021年3月31日止三個月每股盈利(基及攤薄)為人民幣1.33仙,較2020年同期上升25.5%。董事會建議不派發截至2021年3月31日止三個月股息。

在科研服務上,集團旗下“RWS萬全中心”是通過大資料真實臨牀研究重新篩選和組團現有藥品,尋找最佳治療的萬全策。集團成立生物樣品檢測實驗室,配置WatersUPLCMS/MS.XevoTQS,正式對外開放,該實驗室主要服務臨牀研究特別是抗病毒藥物的臨牀研究實驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account